Viatris Names New CLO Amid Leadership Transition
Event summary
- Matthew J. Maletta appointed Chief Legal Officer of Viatris, effective February 9, 2026.
- Brian Roman, current CLO, transitions out after over 20 years of service, staying until April 1, 2026 for transition.
- Maletta brings nearly 30 years of legal experience, including roles at Endo, Allergan, and Skadden.
- Maletta previously led Endo's merger with Mallinckrodt and the spin-off of Par Health.
- Maletta also oversaw the $70 billion sale of Allergan to Actavis.
The big picture
Viatris' appointment of Matthew J. Maletta as CLO underscores the company's focus on leveraging legal expertise to navigate complex healthcare regulations and drive growth. Maletta's extensive experience in both generic and branded pharmaceutical sectors positions him to support Viatris' mission of bridging the divide between these segments. The transition also highlights the importance of stable leadership in a highly regulated industry, where legal and compliance teams play a critical role in operational success.
What we're watching
- Strategic Alignment
- How Maletta's experience in mergers and acquisitions will shape Viatris' growth strategy.
- Regulatory Compliance
- Whether Maletta can maintain Viatris' strong legal and compliance team amid regulatory challenges.
- Transition Impact
- The pace at which Maletta can integrate into Viatris' operations and build on Roman's legacy.
Related topics